Risk of breast cancer recurrence in patients receiving manual lymphatic drainage: a hospital-based cohort study

doi:10.2147/TCRM.S79118

Chia Nan University of Pharmacy & Science Institutional Repository > 環境永續暨休閒學院 > 休閒保健管理系(所) > 期刊論文 > Item 310902800/29582

jsp.display-item.identifier=請使用永久網址來引用或連結此文件: https://ir.cnu.edu.tw/handle/310902800/29582

標題:	Risk of breast cancer recurrence in patients receiving manual lymphatic drainage: a hospital-based cohort study
作者:	Hsiao, Pei-Chi Liu, Jung-Tai Lin, Chien-Liang Chou, Willy Lu, Shiang-Ru
貢獻者:	休閒保健管理系
關鍵字:	breast cancer lymphedema manual lymphatic drainage
日期:	2015
上傳時間:	2016-04-19 19:01:01 (UTC+8)
出版者:	Dove Medical Press Ltd
摘要:	Background: This retrospective cohort study evaluated whether manual lymphatic drainage (MLD) therapy increases the risk of recurrence of breast cancer.Methods: We analyzed 1,106 women who were diagnosed with stage 0-3 breast cancer between 2007 and 2011 and experienced remission after surgery and adjuvant therapy. The patients were divided into two groups: group A (n=996), in which patients did not participate in any MLD therapy, regardless of whether they developed breast cancer-related lymphedema (BCRL) after cancer treatment; and group B (n=110), in which patients participated in MLD therapy for BCRL. All patients were monitored until October 2013 to determine whether breast cancer recurrence developed, including local or regional recurrence and distant metastasis. Patients who developed cancer recurrence prior to MLD therapy were excluded from analysis. Risk factors associated with cancer recurrence were evaluated using Cox proportional hazards models.Results: During the monitoring period, 166 patients (15.0%) developed cancer recurrence, including 154 (15.5%) in group A and 12 (10.9%) in group B. The median period from surgery to cancer recurrence was 1.85 (interquartile range 1.18-2.93) years. Independent risk factors for cancer recurrence were tumor histological grading of grade 3, high number (>3) of axillary lymph node invasion, and a large tumor size (>5 cm). Factors protecting against recurrence were positive progesterone receptor status and receiving radiation therapy. Receiving MLD therapy was not an outcome factor in multivariate analyses (hazard ratio 0.71, 95% confidence interval 0.39-1.29, P=0.259).Conclusion: MLD is a gentle procedure that does not increase the risk of breast cancer recurrence in patients who develop BCRL.
關聯:	Therapeutics And Clinical Risk Management, v.11 , pp.349-357
显示于类别:	[休閒保健管理系(所)] 期刊論文

文件中的档案:

档案	描述	大小	格式	浏览次数
29582.pdf		380Kb	Adobe PDF	330	检视/开启
index.html		0Kb	HTML	1578	检视/开启

在CNU IR中所有的数据项都受到原著作权保护.

TAIR相关文章

数据加载中.....